Celgene's Abraxane: Two Month Survival Boost In Pancreatic Cancer Trial

New details were released Tuesday from the phase III study of Celgene's Abraxane in pancreatic cancer.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!